Live
- India Faces Blow as Pacer Mohammed Shami Ruled Out for Remainder of Australia Series
- Farmer’s Day Celebrations Held at Palem Agricultural Research Center, Nagarkurnool
- Biden Pardon: Joe Biden Commutes Death Sentences of 37 Inmates, Including Child Killers and Mass Murderers
- South Korea: Yoon believes impeachment trial takes priority over martial law probe
- Strict Action for Non-Adherence to Time Management - DMHO Dr. Swarajya Lakshmi
- Joyful Semi-Christmas Celebrations at Sri Saraswathi International School
- Over 13.29 lakh houses approved for rural poor in Maharashtra: Shivraj Chouhan
- District Collector Urges Timely Completion of Indiramma Housing Scheme Survey
- Digital Arrest Scam: Hyderabad Man Duped of ₹7 Lakhs by Fake Crime Branch Police Callers
- Sukhbir Badal seeks President's Police medal for officer who saved his life
Aurobindo faces lawsuit in US for price inflation
Aurobindo Pharma, Sun Pharma and Lupin are among the 26 drug makers facing a multi-state lawsuit filed in USA by Maryland Attorney General for alleged 'conspiracy to artificially inflate and manipulate prices
Hyderabad: Aurobindo Pharma, Sun Pharma and Lupin are among the 26 drug makers facing a multi-state lawsuit filed in USA by Maryland Attorney General for alleged 'conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for generic drugs sold across the United States'.
Attorney General Brian E Frosh in a statement issued on Wednesday said the new complaint, filed in the US District Court for the District of Connecticut, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and the complaint names 26 corporate defendants and 10 individual defendants.
The lawsuit seeks damages, civil penalties, and actions by the court to restore competition to the generic drug market. In addition to Maryland, the suit was joined by the attorneys general of all the other states in the USA.
"This complaint shows again a tangled web of industry executives and sales people who met with each other on social outings and at trade shows, and had conversations that laid the groundwork for the illegal agreements.
Their price-fixing schemes cost patients, the State of Maryland and health insurance companies billions of dollars in unnecessary health care expenditures," Frosh said.
